# 24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Study · id `cardio:ct-nct02182830` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02182830](<https://clinicaltrials.gov/study/NCT02182830>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02182830

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 166 participants.

## Technical summary

Registry record NCT02182830. Randomized; double masking; primary purpose treatment. Start 2014-07-25 (actual); primary completion 2017-05-18 (actual). Results posted on 2018-07-31.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 166 participants (enrolled count; ClinicalTrials.gov record NCT02182830, source copy `cardio:ctgov-nct02182830-2018-07-31`, retrieved 2026-10-26)
- Started: 2014-07-25 (actual) (ClinicalTrials.gov record NCT02182830, source copy `cardio:ctgov-nct02182830-2018-07-31`, retrieved 2026-10-26)
- Primary completion: 2017-05-18 (actual) (ClinicalTrials.gov record NCT02182830, source copy `cardio:ctgov-nct02182830-2018-07-31`, retrieved 2026-10-26)
- Completion: 2017-05-18 (actual) (ClinicalTrials.gov record NCT02182830, source copy `cardio:ctgov-nct02182830-2018-07-31`, retrieved 2026-10-26)
- Results first posted: 2018-07-31 (ClinicalTrials.gov record NCT02182830, source copy `cardio:ctgov-nct02182830-2018-07-31`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02182830, source copy `cardio:ctgov-nct02182830-2018-07-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02182830-2018-07-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: 24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension
- Condition: Diabetes Mellitus, Type 2
- Condition: Hypertension
- Intervention (Drug): Empagliflozin low dose
- Intervention (Drug): placebo
- Intervention (Drug): Empagliflozin high dose
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension (`cardio:pubmed-30786754`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: eafffc8b1fe5e8628aadc1bba995b292cebbf5d4fe47da9da3c43b08da69acf8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
